Noninvasive monitoring of mRFP1- and mCherry-labeled oncolytic adenoviruses in an orthotopic breast cancer model by spectral imaging

Molecular Imaging

Volumn 9, Issue 2, 2010, Pages 59-75

  Borovjagin, Anton V ^a,b   McNally, Lacey R ^a,b   Wang, Minghui ^a,b   Curiel, David T ^a,b   MacDougall, Mary J ^a,b   Zinn, Kurt R ^a,b  

^a Univ of Alabama School of Dentistry   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER MODELS; BREAST CANCER XENOGRAFTS; DIRECT VISUALIZATION; FLUORESCENT REPORTER; IMAGING APPLICATIONS; IN-VIVO; INTRATUMORAL INJECTION; NON-INVASIVE MONITORING; ORTHOTOPIC; OSCILLATORY DYNAMICS; QUANTITATIVE ASSESSMENTS; QUANTITATIVE POLYMERASE CHAIN REACTION; RED FLUORESCENT PROTEINS; SPECTRAL IMAGING; TRANSGENE EXPRESSION; TUMOR MODELS; VIRAL CAPSIDS; VIRAL REPLICATION; VIROTHERAPY; VIRUS TRACKING;

FLUORESCENCE; LABELING; PROTEINS; TUMORS; VIRUSES; VISUALIZATION;

POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENT; FLUORESCENT DYE; ONCOLYTIC VIRUS; PHOTOPROTEIN; RED FLUORESCENT PROTEIN;

ADENOVIRUS; ANIMAL; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CHEMISTRY; DRUG SCREENING; FEMALE; FLUORESCENCE MICROSCOPY; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR CLONING; MOUSE; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PHYSIOLOGY; REPRODUCIBILITY; TUMOR CELL LINE; VIRION; VIROLOGY; VIRUS CAPSID; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CAPSID; CELL LINE, TUMOR; CLONING, MOLECULAR; FEMALE; FLUORESCENT DYES; HUMANS; LUMINESCENT PROTEINS; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; REPRODUCIBILITY OF RESULTS; VIRION; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951846085     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2010.00003     Document Type: Article

References (37)

1. Nettelbeck DM . Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis. Anticancer Drugs 2003; 14: 577- 84.
2. Makower D, Rozenblit A, Kaufman H, et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 2003; 9: 693- 702 .
3. Ahn M, Lee SJ, Li X, et al. Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter. Cancer Gene Ther 2009; 16: 73- 82 .
4. Ranki T, Kanerva A, Ristimäki A, et al. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Ther 2007; 14: 58- 67 .
5. de Martin R, Raidl M, Hofer E, et al. Adenovirus-mediated expression of green fluorescent protein. Gene Ther 1997; 4: 493- 5.
6. Chen BE, Lendvai B, Nimchinsky EA, et al. Imaging highresolution structure of GFP-expressing neurons in neocortex in vivo. Learn Mem 2000; 7: 433- 41.
7. MacLaren DC, Gambhir SS, Satyamurthy N, et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 1999; 6: 785- 91. (Pubitemid 29243651)
8. Chaudhuri TR, Cao Z, Rodríguez-Burford C, et al. A noninvasive approach for monitoring breast tumor cells during therapeutic intervention. Cancer Biother Radiopharm 2007; 17: 205- 12.
9. Mittal SK, McDermott MR, Johnson DC, et al. Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res 1993; 28: 67- 90.
10. Vales LD, Darnell JE . Promoter occlusion prevents transcription of adenovirus polypeptide IX mRNA until after DNA replication. Genes Dev 1989; 3: 49- 59.
11. Le LP, Everts M, Dmitriev IP, et al. Fluorescently-labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging 2004; 3: 105- 16.
12. Meulenbroek RA, Sargent KL, Lunde J, et al. Use of adenovirus protein IX (pIX) to display large polypeptides on the virion-generation of fluorescent virus through the incorporation of pIX-GFP. Mol Ther 2004; 9: 617- 24.
13. Tang Y, Le LP, Matthews QL, et al. Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX. Virology 2008; 377: 391- 400.
14. San Martín C, Glasgow JN, Borovjagin A, et al. Localization of the N-terminus of minor coat protein IIIa in the adenovirus capsid. J Mol Biol 2008; 383: 923- 34.
15. Le LP, Le HN, Dmitriev IP, et al. Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J Natl Cancer Inst 2006; 98: 203- 14 .
16. Shu X, Shaner NC, Yarbrough CA, et al. Novel chromophores and buried charges control color in m Fruits. Biochemistry 2006; 45: 9639- 47.
17. Campbell RE, Tour O, Palmer AE, et al. A monomeric red fluorescent protein. Proc Natl Acad Sci U S A 2002; 99: 7877- 82.
18. Shaner NC, Campbell RE, Steinbach PA, et al. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 2004; 22: 1567- 72.
19. Troy T, Jekic-McMullen D, Sambucetti L, et al. Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models. Mol Imaging 2004; 3: 9- 23.
20. Tam JM, Upadhyay R, Pittet MJ, et al. Improved in vivo whole-animal detection limits of green fluorescent proteinexpressing tumor lines by spectral fluorescence imaging. Mol Imaging 2007; 6: 269- 76.
21. Li J, Le L, Sibley DA, et al. Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology 2005; 338: 247- 58 .
22. Matthews QL, Sibley DA, Wu H, et al. Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. Mol Imaging 2006; 5: 510- 9 .
23. Kimball KJ, Rivera AA, Icyuz M, et al. A novel infectivityenhanced oncolytic adenovirus with a capsid-incorporated dual imaging modality for monitoring virotherapy in ovarian cancer. Mol Imaging 2009; 5: 264-77.
24. Kanerva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptortargeted oncolytic adenovirus. Mol Ther 2003; 8: 449- 58.
25. Chambers A . MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 2009; 69: 13 .
26. Chartier C, Degryse E, Gantzer M, et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli . J Virol 1996; 70: 4805- 10 .
27. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998; 95: 2509- 14.
28. Heise C, Heriston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic antitumoral efficacy [published erratum appears in Nat Med 2000; 6: 412]. Nat Med 2000; 6: 1134- 9.
29. Nettelbeck DM, Rivera AA, Balagué C, et al. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002; 62: 4663- 70.
30. Maizel JV Jr, White DO, Scharff MD . The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968; 36: 115- 25.
31. Ulasov IV, Rivera AA, Han Y, et al. Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells. J Neurosurg 2007; 107: 617- 27 .
32. Ghosh-Choudhury G, Haj-Ahmad Y, Graham FL . Protein IX a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. EMBO J 1987; 6: 1733- 9 .
33. Sargent KL, Ng P, Evelegh C, et al. Development of a sizerestricted pIX-deleted helper virus for amplification of helperdependent adenovirus vectors. Gene Ther 2004; 11: 504- 11 .
34. Campbell EM, Perez O, Melar M, et al. Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell. Virology 2007; 360: 286- 93 .
35. Zhu ZB, Lu B, Park M, et al. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer. Int J Oncol 2008; 32: 1179- 88.
36. Sirena D, Lilienfeld B, Eisenhut M, et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 2004; 78: 4454- 62 .
37. Short JJ, Vasu C, Holterman MJ, et al. Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Vi'rus Res 2006; 122: 144- 53 .